Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Dynacure logo — Dynacure develops new treatments for orphan disorders, focus...

Dynacure

Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 program with Ionis.

Founded 2016 France France Series C Total: $100.27M Biotechnology, Health Care +2

General Information

Company Name Dynacure
Founded Year 2016
Location France France
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Life Sciences +1
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Dynacure. To contact Dynacure, visit dynacure.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Dynacure compare?

A PDF of Dynacure and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Dynacure soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Dynacure

Dynacure is a biotechnology startup that specializes in developing new treatments for rare orphan disorders, with a primary focus on Centronuclear Myopathies (CNM) through its Dyn101 program. This initiative aims to address the severe effects of CNM, particularly on young individuals, by altering the expression of the Dynamin 2 protein. To achieve this, Dynacure has collaborated with Ionis Pharmaceuticals, a renowned biopharmaceutical company known for its expertise in RNA-targeted drug discovery. Since its establishment in 2016, Dynacure has successfully attracted substantial investments, including a noteworthy €50.00M Series C investment on 02 April 2020. The investors in this round include Bpifrance, Kurma Partners, Pontifax, Andera Partner, Perceptive Advisors, and Tekla Capital Management. With its headquarters in France, Dynacure is poised to make significant strides in the biotechnology, healthcare, and pharmaceutical industries with its innovative approach to addressing rare orphan disorders.

Business keywords: Rare disease drug development, Orphan disorders, Clinical-stage drug development, Antisense medicine, RNA-targeted drug discovery, Dynamin 2 protein modulation, Centronuclear Myopathies (CNM), Ionis Pharmaceuticals partnership, Investigational medicine development, Clinical trial advancement, Biopharmaceutical research, Dyn101 program, Orphan disease therapeutics, Rare disease treatment innovation

Services & Products

Development and execution of RNA-targeted therapies for oncology

Target Customers

Patients with cancer and healthcare professionals

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series C €50.00M 6
Bpifrance Kurma Partners Pontifax
Bpifrance, Kurma Partners +4
02 Apr 2020
Series A €47.00M 4
Bpifrance Kurma Partners Pontifax
Bpifrance, Kurma Partners +2
06 Jul 2018
Seed Round €3.27M 2
IDInvest Partners Kurma Partners
IDInvest Partners, Kurma Partners
08 Nov 2016

Dynacure Alternatives & Competitors

View All Alternatives
Dynacure vs
Dicerna Pharmaceuticals
Dicerna Pharmaceuticals

Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.

Post-IPO Equity
201-500 employees
Biotechnology, Health Care
Dynacure vs
Santaris Pharma
Santaris Pharma

Pioneering RNA-targeted therapies with rapid LNA-based drug development for diverse disease states.

Venture round
Biotechnology, Health Care
Dynacure vs
CLOVERNA
CLOVERNA Japan

RNA targeted drug discovery

1 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Dynacure

Dynacure develops new treatments for orphan disorders, focusing on CNM through Dyn101 program with Ionis.
Dynacure was founded in 2016.
Dynacure is headquartered in France.
Dynacure operates in Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on Rare disease drug development, Orphan disorders, Clinical-stage drug development and Antisense medicine. Its customers include Patients with cancer and healthcare professionals.
Dynacure has completed 3 funding rounds, raising a total of $100.27M. The latest funding stage is Series C.
Dynacure offers: Development and execution of RNA-targeted therapies for oncology.
Top alternatives and competitors to Dynacure include Dicerna Pharmaceuticals, Santaris Pharma, CLOVERNA, Jupiter Neurosciences, Inc., Versantis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Dynacure and Dicerna Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Dynacure, https://bouncewatch.com/company/dynacure, updated 1 September 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes